Quality by Design: Adding Another Dimension to Outsourcing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Quality by Design: Adding Another Dimension to Outsourcing
FDA's quality-by-design initiative is gradually reshaping the paradigm for pharmaceutical manufacturing and the opportunities and challenges in outsourcing.

Pharmaceutical Technology
Volume 34, Issue 1, pp. 40-44

For the second case of when a sponsor company and the contract-service provider partner on the development effort, Oates offers an example of a recent QbD project between Pfizer and a contract-service provider. "The contract-service provider determined the critical attributes of a functional excipient in the drug-product formulation and their impact on product performance," she says. This information was used to determine the specification for the material. The contract-service provider also used computational fluid dynamics to model the spray-drying process and engineering models to take it to commercial scale. Designs of experiment for several unit operations were also completed by the contract-service provider. "Most importantly, scientists from the contract-service provider were vital members of the development team and routinely participated in key meetings," she adds. For example, they were also given author access to the documentation system, so they could directly write their sections of the regulatory submission. "This extent of collaboration, where the contractor is a true partner in the development process, is unique in our experience," says Oates. "However, it is likely to become more common as the adoption of QbD accelerates, and outsourcing of development efforts due to technology or cost-drivers increases."

Vendor selection. QbD comes into play not only in the execution of an outsourced project but also in vendor selection. "Material characterization and identification of significant quality attributes of raw materials (both drug substance and excipients) is an important aspect of process understanding," says Oates. "In some cases, vendors are willing to work with the sponsor to provide extensive material-characterization data. This is often the case if the vendor is supplying a new or unique material, but may not be the case for commodity items. Once the necessary quality attributes are identified, vendors who can routinely supply acceptable material must be qualified for use. If API manufacturing is outsourced, the sponsor must understand and include known critical quality attributes into the purchasing and quality agreements. Finally, if a drug product developed using QbD, perhaps including a novel technology and control strategy, will be outsourced, the vendor must have the technical sophistication and quality systems to effectively manufacture and test the product."

Supplier performance. QbD also has the potential to change supplier metrics. "Although typical measurements will still be used to evaluate supplier performance, additional ones will be added," says Oates. "These may include the ability of the supplier to control the product and process by effectively using the design space; the supplier's commitment to continuous quality verification by evaluating and communicating to the sponsor the process data that is generated by all lots; and the supplier's willingness to facilitate regulatory changes to modify or enlarge the design space as allowed by the data."

Contract manufacturers' views

Contract manufacturers also recognize the changing expectations of sponsor companies. "Applying the principles of QbD requires an holistic approach to drug development and manufacturing, both for contractors and pharmaceutical companies," says Ian Elvins, executive vice-president of global quality at Lonza (Basel, Switzerland), a contract manufacturer of small-molecules and biologic-based APIs. "Therefore the principles of QbD can be and should be applied throughout the life of a drug from familiarization and development through qualification, validation, and production. The QbD approach will be used to streamline development, to identify potential risks, and to develop ability in products and processes. The risk assessment allows us to tailor the process development work to the goals needed at a specific point of a product's and process's life cycle. As an API runs through the phases of its life cycle, the process knowledge grows together with the increasing needs for information."

Lonza is adopting the principles of QbD for both chemical and biologic APIs. It recently made two bolt-on acquisitions to enhance its technology positions and QbD capabilities for biopharmaceuticals. In November 2009, it acquired Algonomics (Gent, Belgium), a contract research organization providing immunogenicity screening platforms. In 2007, it acquired AggreSolve, which provides an in-silico protein analysis platform to solve problems associated with protein aggregation. "The Algonomics and AggreSolve technologies enable us to identify drug safety or manufacturing challenges early on, which provides the opportunity to address them and create safer and more cost-effective products," says Elvins.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here